Search results for " real-life"

showing 10 items of 14 documents

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct

Different skin prick test sensitization patterns do not influence the response to omalizumab in severe asthma

2017

Malemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyEffectivenessOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexmedicineHumansImmunology and AllergyAnti-Asthmatic AgentsSensitizationRetrospective StudiesSkin Testsbusiness.industryEffectiveneReal-lifeImmunoglobulin EEffectiveness; Omalizumab; Pollen sensitized; Real-life; Severe asthma; Immunology and Allergy; ImmunologyDermatologyAsthmaPollen sensitizedTest (assessment)Respiratory Function Testsmedicine.anatomical_structureTreatment Outcomeeffectiveness; omalizumab; pollen sensitized; real-life; severe asthmaFemaleImmunizationbusinessmedicine.drug
researchProduct

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

2020

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

2023

Background and aims: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after HCV eradication by direct-acting antivirals in patients with cirrhosis. Methods: HCC occurrence was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the post-treatment variables associated with de-novo HCC; their predictive power was presented in a nomogram. Results: After the end of therapy (median follow-up:28.47 months), among 2064 SVR patients, 119 (5.8%) developed de-novo HCC. The HCC incidence was 1.90%, 4.21%, 6.47% a…

Settore MED/12Real-life cohort.HepatologyDirect-acting antiviral; HCC; Long term outcomes; Predictive factors; Real-life cohortGastroenterologyReal-life cohortLong term outcomeHCCPredictive factorDirect-acting antiviralLong term outcomesPredictive factors
researchProduct